LWY713 is a PROTAC-based FLT3 degrader (DC50=0.64 nM) that selectively induces FLT3 degradation through a cereblon and proteasome-dependent mechanism. It inhibits cell proliferation and causes G0/G1 phase arrest and apoptosis (apoptosis) in MV4-11 cells. In MV4-11 xenograft models, LWY713 demonstrates significant in vivo antitumor activity. The E3 ligase ligand and linker consist of Lenalidomide-Glycolic acid, while the target protein ligand's active control is NaproxenGilteritinib.